CYP19A1 and breast carcinoma: Recent retrospective analyses from two large randomized trials comparing tamoxifen with aromatase inhibition as treatment for early stage breast cancer in post-menopausal women demonstrated no impact of CYP2D6 genotype on outcome [25,26].